ArticleCureus2026
Disciform Keratitis That Improves With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor Treatment for Ovarian Cancer but Recurs Upon Discontinuation of Treatment.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The patient was a 73-year-old woman. She underwent surgery for ovarian cancer but needed chemotherapy because tumor cells were observed at the resection margin. She was administered niraparib tosilate hydrate, a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, for five years; however, she developed severe malaise that made daily life difficult, rendering continued treatment impossible. Consequently, the PARP inhibitor was discontinued, and her physical condition improved. One year after discontinuation, she developed ocular herpes zoster, followed by disciform keratitis, leading to her presentation at our hospital. Examination of the right eye revealed disciform corneal edema and opacity, resulting in a diagnosis of disciform keratitis. Varicella-zoster virus (VZV) DNA was detected via PCR analysis of the aqueous humor; treatment with oral valacyclovir and topical betamethasone was initiated. Subsequently, the disciform keratitis resolved with continued topical betamethasone therapy. However, ovarian cancer recurrence was observed, and another PARP inhibitor, olaparib, was prescribed. She again experienced malaise, necessitating the discontinuation of the PARP inhibitor. One month after discontinuation, a recurrence of disciform keratitis was observed. Frequent topical betamethasone administration was initiated, resulting in the resolution of the disciform keratitis. These findings suggest the possibility that in patients with cancer who are immunocompromised due to treatment with PARP inhibitors, an immune response against VZV does not occur; however, when immune function recovers upon discontinuation of the PARP inhibitor, the immune response against VZV is reactivated, resulting in the recurrence of disciform keratitis. Thus, when managing patients with cancer, it is essential to monitor fluctuations in immune response while addressing ocular infections and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.